Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.

8019 Background: ASCT is the procedure of choice in poor risk NHL, however conditioning regimens is a challenging procedures because safely delivered only in younger and clinically fit patients, thus new approaches are suggested to enhance its applicability. To extend the probability of cure to pts not eligible to standard ASCT from 12/2003 to 7/2007, 60 high-risk CD20+ NHL pts have been included in a phase II study with myeloablative Y90-Ibritumomab Tiuxetan, supported by ASCT. Methods: CD20+ relapsed/refractory or newly diagnosed high-risk NHL adults defined by IPI>3 DLBCL, MCL or transformed BCL, with no upper limit of age not eligible to standard ASCT have been enrolled. Pts were required to collect ≥9 x 106 CD34+cells/kg. Y90-Ibritumomab Tiuxetan (0.8-1.2 mci/kg) was administered after rituximab based HDCT: DHAP x 3, CTX 5-7g/mq followed stem cells collection, Ara-C 12-24 g/mq with 2x106 CD34+ cells/kg support. To hasten hematopoietic recovery, each pt received two stem-cell autograft of 2x106 CD34+ ...